8 active not recruiting. 8 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Active not recruiting 8 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow Mood Disorders: new trials by email Literature Review of Mood Disorders trials Research Report on Mood Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects Selegiline Transdermal Delivery System - Major Depressive Disorder (MDD) | Phase 1 | Active not recruiting | Corium Innovations, Inc. | 232 | 2026-08-23 | 2026-08-31 |
| Psilocybin for Treatment-Resistant Depression in Autism Psilocybin - Treatment Resistant Depression, Autism Spectrum Disorder | Phase 1 | Active not recruiting | Centre for Addiction and Mental Health | 18 | 2024-11-01 | 2026-10-26 |
| Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression Psilocybin, Functional MRI - Bipolar Depression | Phase 1 | Active not recruiting | University Health Network, Toronto | 30 | 2024-10-09 | 2026-08-10 |
| ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression ELE-101, ELE-101 Placebo - Healthy Volunteers, Major Depressive Disorder | Phase 1 / Phase 2 | Active not recruiting | Eleusis Therapeutics | 84 | 2022-10-27 | 2025-02-19 |
| The Safety, Tolerability, and Effectiveness of Quetiapine in Postpartum Depression Quetiapine - Postpartum Depression | Phase 1 | Active not recruiting | Verinder Sharma | 22 | 2022-03-18 | 2025-03-05 |
| Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans 0.1 mg/kg Dimethyltryptamine (DMT), 0.3 mg/kg Dimethyltryptamine (DMT) - Major Depressive Disorder, Depression | Phase 1 | Active not recruiting | Yale University | 30 | 2021-03-17 | 2025-08-03 |
| Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder Low Dose Psilocybin, Placebo, Medium Dose Psilocybin - Major Depressive Disorder | Phase 1 | Active not recruiting | Yale University | 18 | 2018-02-27 | 2025-11-05 |
| Smoking Cessation for Depressed Smokers Smoking Cessation Treatment, Nicotine Replacement Therapy, CBASP - Smoking, Depression | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 91 | 2007-06-28 | 2026-06-15 |
Depressive Disorder, Major (6) · Depression (4) · Depressive Disorder, Treatment-Resistant (2) · Autism Spectrum Disorder (1) · Bipolar Disorder (1) · Depression, Postpartum (1) · Smoking (1)
Depressive Disorder (8) · Mental Disorders (8) · Behavior (4) · Behavioral Symptoms (4) · Bipolar and Related Disorders (1) · Child Development Disorders, Pervasive (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Neurodevelopmental Disorders (1) · Pregnancy Complications (1) · Puerperal Disorders (1) · Urogenital Diseases (1)
Psilocybin (3) · Magnetic Resonance Imaging (1) · N,N-Dimethyltryptamine (1) · Nicotine Replacement Therapy (1) · Quetiapine Fumarate (1)
Yale University (2) · Centre for Addiction and Mental Health (1) · Corium Innovations, Inc. (1) · Eleusis Therapeutics (1) · M.D. Anderson Cancer Center (1) · University Health Network, Toronto (1) · Verinder Sharma (1)
Canada (3) · United States (3) · Bulgaria (1) · United Kingdom (1)
Deepak D'Souza, MD (1) · Hsiang-Yuan Lin, MD (1) · Jan Blalock, PhD (1) · Joshua Rosenblat, MD, MSc (1) · Neel Bhatt (1) · Verinder Sharma, MB (1)
R01MH076776 (1), R01MH087692 (1)